Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Department of Colorectal and Anal Surgery Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510515, China.
BMC Cancer. 2024 Jan 2;24(1):26. doi: 10.1186/s12885-023-11766-6.
Epigenetic alterations contribute greatly to the development and progression of colorectal cancer, and effect of aberrant miR-622 expression is still controversial. This study aimed to discover miR-622 regulation in CRC proliferation.
miR-622 expression and prognosis were analyzed in clinical CRC samples from Nanfang Hospital. miR-622 regulation on cell cycle and tumor proliferation was discovered, and FOLR2 was screened as functional target of miR-622 using bioinformatics analysis, which was validated via dual luciferase assay and gain-of-function and loss-of-function experiments both in vitro and in vivo.
miR-622 overexpression in CRC indicated unfavorable prognosis and it regulated cell cycle to promote tumor growth both in vitro and in vivo. FOLR2 is a specific, functional target of miR-622, which negatively correlates with signature genes in cell cycle process to promote CRC proliferation.
miR-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation, proposing a novel mechanism and treatment target in CRC epigenetic regulation of miR-622.
表观遗传改变在结直肠癌的发生和发展中起重要作用,miR-622 表达异常的作用仍存在争议。本研究旨在探讨 miR-622 在 CRC 增殖中的调控作用。
分析南方医院临床结直肠癌样本中 miR-622 的表达和预后。通过生物信息学分析筛选出 miR-622 的功能靶基因 FOLR2,通过双荧光素酶报告基因检测和体外及体内的功能获得和功能丧失实验验证 miR-622 对细胞周期和肿瘤增殖的调控作用。
CRC 中 miR-622 的过表达预示着不良的预后,它通过调节细胞周期促进肿瘤在体外和体内的生长。FOLR2 是 miR-622 的特异性功能靶基因,与细胞周期过程中的特征基因呈负相关,促进 CRC 增殖。
miR-622 通过靶向 FOLR2 上调细胞周期过程促进 CRC 增殖,为 CRC 中 miR-622 的表观遗传调控提供了新的机制和治疗靶点。